Ajit K. Bharti, PhD
Research Assistant Professor
Boston University School of Medicine
Dept of Medicine
Hematology & Medical Oncology

PhD, Ranchi University
MS, Ranchi University

Ajit Bharti, PhD. Research Assistant Professor of Medicine:
Dr. Bharti received his PhD from Ranchi University, India. After a brief stint as a research scientist at the All India Institute of Medical Sciences, New Delhi, he joined Dr. Donald W. Kufe’s lab at the Dana-Farber Cancer Institute. After post-doctoral training, he continued to work as an instructor and contributed to understand the DNA-damage response pathway, particularly DNA-DSB caused by topoI inhibitors. TopoI inhibitors are used extensively to treat solid tumors, however, the response rate is low and the drug resistance mechanism is not understood. Dr. Bharti’s lab defined the mechanism of resistance, identified topoI-pS10 as the key molecular determinant of this pathway, and validated that as a potential predictive biomarker for this class of drugs. This IHC-based biomarker is retrospectively validated in CRC and GC. The discovery of topoI-pS10 as a predictive biomarker will significantly enhance the clinical utility of topoI inhibitors and will change the response rate in patient population

Boston Medical Center

Developing a Predictive Biomarker for Topol Inhibitors
04/01/2011 - 03/31/2013 (PI)
Predictius Bioscience Inc.

To determine the synergistic effect of MLN9708 with irinotecan in solid tumor and use of a predictiv
01/27/2014 - 01/27/2016 (PI)
Millennium Pharmaceuticals Inc

Role of c-Met in SCLC and Potential for Novel Therapy
09/19/2008 - 02/28/2013 (PI)
Univ of Chicago NIH-NCI

Role of Neuroregulin/erbB Signaling in the Adult Heart
07/01/2006 - 06/30/2007 (PI)
Vanderbilt University Medical Center NIH-NHLBI
7 R01 HL068144


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Ando K, Hu Q, Fujimoto Y, Jogo T, Nakanishi R, Hisamatsu Y, Kimura Y, Oki E, Bharti A, Mori M. [The Efficacy of topo ?-pS10 Expression in Gastric Cancer as a Predictive Biomarker for Irinotecan Use]. Gan To Kagaku Ryoho. 2021 Mar; 48(3):331-335. PMID: 33790151
  2. Ando K, Ozonoff A, Lee SY, Voisine M, Parker JT, Nakanishi R, Nishimura S, Yang J, Grace Z, Tran B, Diefenbach TJ, Maehara Y, Yasui H, Irino T, Salgia R, Terashima M, Gibbs P, Ramanathan RK, Oki E, Mori M, Kulke M, Hartshorn K, Bharti A. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clin Colorectal Cancer. 2020 Dec 10.View Related Profiles. PMID: 33731288
  3. Matsuoka H, Ando K, Swayze EJ, Unan EC, Mathew J, Hu Q, Tsuda Y, Nakashima Y, Saeki H, Oki E, Bharti AK, Mori M. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer. PLoS One. 2020; 15(8):e0228002.View Related Profiles. PMID: 32764831; PMCID: PMC7413750; DOI: 10.1371/journal.pone.0228002;
  4. Ando K, Tohme YH, Srinivasiah A, Taylor-Parker J, Harrington Y, Shah AK, Oki E, Brahmandam M, Bharti AK. Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors. J Histochem Cytochem. 2018 08; 66(8):549-561.View Related Profiles. PMID: 29587004; PMCID: PMC6071180; DOI: 10.1369/0022155418766503;
  5. Ando K, Shah AK, Sachdev V, Kleinstiver BP, Taylor-Parker J, Welch MM, Hu Y, Salgia R, White FM, Parvin JD, Ozonoff A, Rameh LE, Joung JK, Bharti AK. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. Oncotarget. 2017 Jul 04; 8(27):43733-43751.View Related Profiles. PMID: 28415827; PMCID: PMC5546437; DOI: 10.18632/oncotarget.16376;
  6. Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D. Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156.View Related Profiles. PMID: 26267657; PMCID: PMC4534190; DOI: 10.1371/journal.pone.0135156;
  7. Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand TM, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84. PMID: 24327519; PMCID: PMC4286701; DOI: 10.1158/1535-7163.MCT-13-0109;
  8. Icli B, Bharti A, Pentassuglia L, Peng X, Sawyer DB. ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochem Biophys Res Commun. 2012 Feb 3; 418(1):116-21. PMID: 22244893; PMCID: PMC3273580; DOI: 10.1016/j.bbrc.2011.12.144;
  9. Tamayo AG, Slater L, Taylor-Parker J, Bharti A, Harrison R, Hung DT, Murphy JR. GRP78(BiP) facilitates the cytosolic delivery of anthrax lethal factor (LF) in vivo and functions as an unfoldase in vitro. Mol Microbiol. 2011 Sep; 81(5):1390-401.View Related Profiles. PMID: 21797942; PMCID: PMC4041151; DOI: 10.1111/j.1365-2958.2011.07770.x;
  10. Murshid A, Chou SD, Prince T, Zhang Y, Bharti A, Calderwood SK. Protein kinase A binds and activates heat shock factor 1. PLoS One. 2010; 5(11):e13830. PMID: 21085490; PMCID: PMC2976705; DOI: 10.1371/journal.pone.0013830;
Showing 10 of 28 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 28 publications over 17 distinct years, with a maximum of 6 publications in 2005


In addition to these self-described keywords below, a list of MeSH based concepts is available here.

bi-marker development
Post translational modification
Contact for Mentoring:

650 Albany St Evans Biomed Research Ctr
Boston MA 02118
Google Map

Bharti's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department